ATRIA Stroke Risk Score for Atrial Fibrillation
Predicts stroke/thromboembolism risk in AF patients. Continuous score 0–15. Developed from the ATRIA study (13 000+ AF patients).
Score interpretation
Low stroke risk. Annual stroke rate <1%.
→ Anticoagulation may not be required. Discuss risk-benefit with patient.
Moderate stroke risk. Annual stroke rate 1–2%.
→ Consider anticoagulation (NOAC preferred). Assess bleeding risk concurrently.
High stroke risk. Annual stroke rate >2%.
→ Anticoagulation strongly recommended (NOAC preferred). Minimise modifiable stroke risk factors.
Interpretation bands for the ATRIA Stroke. Apply clinical judgement and local guidance.
References
- Singer DE et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250.
Related
Curated clinical cross-links plus same-class fallbacks.
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Vernakalant · Atrial-selective antiarrhythmic
- Aspirin (Loading Dose) · Antiplatelet — ACS / Ischaemic Stroke
- Alteplase (tPA) · Thrombolytic — Ischaemic Stroke / Massive PE
- Bivalirudin · Anticoagulation
- Edoxaban (AF Stroke Prevention / VTE) · Direct Factor Xa Inhibitor (DOAC)
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.